Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
January 02, 2024 16:05 ET
|
Windtree Therapeutics
The new preclinical data further supports istaroxime clinical data from three Phase 2 studies Arrythmias can be a serious complication of current rescue therapies for treatment of patients with acute...
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
December 18, 2023 08:00 ET
|
Windtree Therapeutics
SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3 The Company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime...
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
November 16, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
November 09, 2023 16:15 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
November 08, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree to Present at the ThinkEquity Conference on October 19th in New York City
October 12, 2023 07:30 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th
October 10, 2023 07:30 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
October 03, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office
August 23, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
August 07, 2023 16:05 ET
|
Windtree Therapeutics
Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3;Study start-up for a Phase 2 SCAI Stage C cardiogenic shock study underway Completed $12.4...